


GPrX Market Review 2018

Antidepressants

Market Changes




GPrX analysis shows prescription items for antidepressants in UK primary care rose 4.97% between 2017 and 2018 to 86.5m.

In this period, reimbursement spend on antidepressants has fallen 11.7% to £268.8m in 2018.

One of the key drivers for the change in spend is the reduction in price of the TCA, trazodone.

2018 Market Share by Antidepressant Type



Selective serotonin reuptake inhibitors (SSRIs) were the most frequently prescribed antidepressant type in 2018, with a market share of prescriptions of 53.7%, flat on 2017.

TCAs accounted for 23.4% of antidepressant prescription items in 2018, down 0.9 percentage points from 24.3% in 2017.

2018 Performance Index

Top 10 Prescribed SSRI Antidepressant Brands			
Market share of prescriptions	Change in % MS		
Brand	2018		vs 2017
Sertraline (Various)	38.42%	▲	3.19%
Citalopram (Various)	36.82%	▼	-2.31%
Fluoxetine (Various)	17.88%	▼	-0.72%
Paroxetine (Various)	3.44%	▼	-0.26%
Escitalopram (Various)	2.73%	▲	0.09%
Fluoxetine (Medreich)	0.26%	▲	0.05%
Seroxat (GlaxoSmithKline)	0.10%	▼	0.00%
Oxactin (Discovery Pharma)	0.07%	▼	-0.01%
Fluvoxamine (Various)	0.06%	▼	0.00%
Prozac (Eli Lilly)	0.05%	▼	-0.01%

Although the market share of prescription items for SSRIs remained flat year on year, in absolute terms, prescription items increased 5.1% versus 2017, to 46.5m in 2018.

Within this market, sertraline has seen the greatest growth in market share, up 3.2 percentage points to 38.4% of market share of prescriptions in 2018.